Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes

Cellular and Molecular Immunology

Volumn 6, Issue 2, 2009, Pages 97-103

  Wang, Bing ^a,b   Yao, Kun ^a   Liu, Genyan ^a   Xie, Fangyi ^a   Zhou, Feng ^a   Chen, Yun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b No 81 Hospital of PLA   (China)

Author keywords

Cytotoxic T lymphocyte; Epitope; Epstein Barr virus; Latent membrane protein 2A

Indexed keywords

HLA A2 ANTIGEN; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; UNCLASSIFIED DRUG; CD8 ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS VACCINE; PEPTIDE DERIVATIVE; CANCER VACCINE; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; GAMMA INTERFERON; MATRIX PROTEIN; PEPTIDE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; BIOINFORMATICS; CD8+ T LYMPHOCYTE; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PREDICTION; VACCINE PRODUCTION; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; EMBRYO; EPSTEIN BARR VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN FUNCTION; TARGET CELL DESTRUCTION; CARCINOMA; CELL CULTURE; COMPUTER SIMULATION; CYTOTOXICITY; GENETICS; IMMUNOLOGY; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PHYSIOLOGY; SECRETION; VIROLOGY;

HUMAN HERPESVIRUS 4;

CANCER VACCINES; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COMPUTER SIMULATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; NASOPHARYNGEAL NEOPLASMS; PEPTIDES; VIRAL MATRIX PROTEINS;

EID: 68549107886     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.13     Document Type: Article

References (31)

1. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol. 2000;53:248-254.
2. Dolcetti R, Masucci MG. Epstein-Barr virus: induction and control of cell transformation. J Cell Physiol. 2003;196:207-218. (Pubitemid 36775867)
3. Young LS, Rowe M. Epstein-Barr virus, lymphomas and Hodgkin's disease. Semin Cancer Biol. 1992;3:273-284.
4. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375:685-688.
5. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A. 1997;94:12616-12621. (Pubitemid 27492577)
6. Pai S, Khanna R. Role of LMP1 in immune control of EBV infection. Semin Cancer Biol. 2001;11:455-460. (Pubitemid 33105024)
7. Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene. 1997;15:1851-1858. (Pubitemid 27478628)
8. Straathof KC, Leen AM, Buza EL, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005;175:4137-4147.
9. Lalonde A, Avila-Carino J, Caruso M, de Campos-Lima PO. Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2. Virology. 2007;361:253-262. (Pubitemid 46574842)
10. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219. (Pubitemid 30099526)
11. Schuler MM, Nastke MD, Stevanovikc S. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol. 2007;409:75-93.
12. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36:W509-512.
13. Guan P, Doytchinova IA, Zygouri C, Flower DR. MHCPred: A server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res. 2003;31:3621-3624. (Pubitemid 37442210)
14. Guan P, Hattotuwagama CK, Doytchinova IA, Flower DR. MHCPred 2.0: an updated quantitative T-cell epitope prediction server. Appl Bioinformatics. 2006;5:55-61.
15. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123-1131. (Pubitemid 47281407)
16. Demachi-Okamura A, Ito Y, Akatsuka Y, et al. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol. 2006;36:593-602.
17. Chen Y, Yao K, Wang B, Qing J, Liu G. Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A). Cell Mol Immunol. 2008;5:365-372.
18. Berger TG, Feuerstein B, Strasser E, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods. 2002;268:131-140. (Pubitemid 35246159)
19. + T-cell response in a Northern Chinese population. Tissue Antigens. 2003;62:285-295.
20. Kitano M, Kobayashi N, Kawashima Y, et al. Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes Infect. 2008;10:764-772.
21. Gulukota K, Sidney J, Sette A, DeLisi C. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol. 1997;267:1258-1267. (Pubitemid 27192636)
22. Martin W, Sbai H, De Groot AS. Bioinformatics tools for identifying class I-restricted epitopes. Methods. 2003;29:289-298. (Pubitemid 36513445)
23. Pan Y, Zhang J, Zhou L, Zuo J, Zeng Y. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus. Biochem Biophys Res Commun. 2006;347:551-557.
24. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001;93:706-713. (Pubitemid 32695121)
25. Redchenko IV, Rickinson AB. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J Virol. 1999;73:334-342.
26. Bollard CM, Straathof KC, Huls MH, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004;27:317-327.
27. Bontkes HJ, Ruizendaal JJ, Schreurs MW, Kramer D, Meijer CJ, Hooijberg E. Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors. Cell Oncol. 2005;27:175-182. (Pubitemid 41032902)
28. Nagorsen D, Panelli M, Dudley ME, Finkelstein SE, Rosenberg SA, Marincola FM. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells. Gene Ther. 2003;10:1754-1765. (Pubitemid 37121047)
29. + T lymphocyte responses. Blood. 2000;96:1857-1864.
30. + T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol. 2003;77:2757-2761.
31. Lee SP, Thomas WA, Murray RJ, et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 1993;67:7428-7435.